Merck, Sharp and Dohme (MSD) has announced the results of a phase III clinical trial showing telcagepant (MK-0974) significantly improved the relief of migraine pain and associated symptoms two hours after dosing, when compared to placebo.
Furthermore, the firm reported the results of telcagepant 300mg were similar to those recorded for the highest dose of approved migraine therapy zolmitriptan with a lower incidence of adverse events.
Data from the ongoing phase III programme were presented at the annual meting of the American Headache Society, with the company anticipating a submission to regulatory authorities during 2009.
Telcagepant is a novel oral caclitonin gene-related peptide (CGRP) receptor antagonist.
Paul Winner, director of Permiere Research Institute and Palm Beach Headache Centre in West Palm Beach, Florida, said: "These findings provide further support for the development of telcagepant as a potential new acute migraine treatment based on its novel mechanism of action targeting CGRP."
He added these study results show a comparable reduction in migraine pain and associated symptoms with telcagepant and triptan, but with fewer side effects observed with the use of the former compound.
Last month, MSD announced positive results from a phase II trial assessing the efficacy of MK-0974 in migraine patients.See all the latest jobs in Pharmaceutical